Development of innovative antimicrobials against pathogens resistant to antimicrobials[E8]

Extrait de l’avis

Call: Cluster 1 - Health (Single stage - 2027/1). Type of action: HORIZON Research and Innovation Actions. Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed at, tailored towards and contributing to all the following expected outcomes: The scientific and clinical communities have a better understanding of and access to new and innovative products for the treatment of antimicrobial resistant bacteria and fungi, as well as for further clinical investigation. Candidate therapies are available to treat patients for antimicrobial resistant bacteria and fungi, increasing therapeutic options for clinical deployment in the fight against Antimicrobial Resistance (AMR). Scope: The rapid rise of AMR presents a formidable threat to public health, challenging our ability to treat infections that were once easily managed with standard antimicrobials. As pathogens continually adapt and develop resistance to existing drugs, the efficacy of these treatments diminishes, leading to more severe and prolonged illnesses, increased healthcare costs and productivity losses, and higher mortality rates. This escalating crisis underscores an urgent need for viable therapeutic alternatives required to reduce the burden of diseases caused by antibiotic resistance. Innovative solutions are crucial to maintaining effective disease management and safeguarding public health. Propos…[E3]

Les détails de l’avis sont affichés tels que la source les a publiés. Les faits et exigences que nous extrayons sont rédigés en anglais.

• Ouvert àUniversities and research. Étiqueté par SLETOR à partir des mots de l'annonce.
• ConditionEU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.[E4]

• RisqueThis is a grant, not a contract. Grants usually need a proposal against the funder's criteria, may need partners and often need co-funding.[E5]
• InconnuWe read the funder's listing, not the full guidance or application forms.

1. Ouvert aux offres · 29 oct. 2026, 07:41 UTC

   The funder published the call with a future closing date.

   Modifié : status, notice type, published at (enregistrement source Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08))

2. Vu pour la première fois · 28 oct. 2026, 21:22 UTC

   The funder announced the call. Applications have not opened yet.

   Enregistrement source : Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08)

Chaque fait de cette page vient de l'annonce du financeur. Chaque entrée indique l'enregistrement et le champ d'où il a été lu.

1. E1

   The funder is European Commission.

   Source : Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08), champ /metadata/type/0, lu 29 oct. 2026, 07:41 UTC · source ↗ (s’ouvre dans un nouvel onglet)

2. E2

   Proposals must be submitted by 17 Feb 2027, 01:00 Central European time (UTC+1).

   “2027-02-17T00:00:00.000+0000”

   Source : Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08), champ /metadata/deadlineDate/0, lu 29 oct. 2026, 07:41 UTC · source ↗ (s’ouvre dans un nouvel onglet)

3. E3

   The buyer describes the requirement in the notice.

   “Expected Outcome: This topic aims at supporting activities that are enabling or contributing to one or several expected impacts of destination “Tackling diseases and reducing disease burden”. To that end, proposals under this topic should aim to deliver results that are directed…”

   Source : Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08), champ /metadata/descriptionByte/0, lu 29 oct. 2026, 07:41 UTC · source ↗ (s’ouvre dans un nouvel onglet)

4. E4

   EU grant rules apply: check the call conditions for who can apply, consortium rules and co-funding.

   “EU call topic”

   Source : Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08), champ /metadata/type/0, lu 29 oct. 2026, 07:41 UTC · source ↗ (s’ouvre dans un nouvel onglet)

5. E5

   This is an EU call for proposals.

   “31094502”

   Source : Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08), champ /metadata/status/0, lu 29 oct. 2026, 07:41 UTC · source ↗ (s’ouvre dans un nouvel onglet)

6. E6

   Applications open on 29 Oct 2026.

   “2026-10-29T00:00:00.000+0000”

   Source : Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08), champ /metadata/startDate/0, lu 29 oct. 2026, 07:41 UTC · source ↗ (s’ouvre dans un nouvel onglet)

7. E7

   The Funding & Tenders Portal gives the status as open for submission.

   Source : Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08), champ /metadata/status/0, lu 29 oct. 2026, 07:41 UTC · source ↗ (s’ouvre dans un nouvel onglet)

8. E8

   The notice is titled "Development of innovative antimicrobials against pathogens resistant to antimicrobials".

   Source : Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08), champ /metadata/title/0, lu 29 oct. 2026, 07:41 UTC · source ↗ (s’ouvre dans un nouvel onglet)

9. E9

   The EU contribution per grant is up to EUR 11,000,000 (from EUR 3,000,000).

   Source : Development of innovative antimicrobials against pathogens resistant to antimic… (ID HORIZON-HLTH-2027-01-DISEASE-08), champ /metadata/budgetOverview/0, lu 29 oct. 2026, 07:41 UTC · source ↗ (s’ouvre dans un nouvel onglet)

Source: EU Funding & Tenders Portal, © European Union, CC BY 4.0. SLETOR shortened and reformatted the text. Licence des données : Creative Commons Attribution 4.0 (European Commission) ↗ (s’ouvre dans un nouvel onglet). Les coordonnées personnelles figurant dans les avis ne sont ni conservées ni affichées.